PDCD1 and neoplasm: The results indicated that combination treatment with ICGA-A and PD-1/PD-L1 inhibitor 2 significantly increased the frequency of anti-tumor M1-type TAMs, while having no significant effect on immunosuppressive M2-type TAMs (Figures 6B, E).